MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Merus N.V. Total Assets 2011-2025 | MRUS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 783 M | 455 M | 377 M | 457 M | 231 M | 263 M | 250 M | 236 M | 76 M | 38.8 M | 4.3 M | 17.2 M | 10.6 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 783 M | 4.3 M | 246 M |
Quarterly Total Assets Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 904 M | 980 M | 731 M | 783 M | 845 M | 892 M | 498 M | 455 M | 492 M | 364 M | 339 M | 377 M | 415 M | 445 M | 418 M | 457 M | 356 M | 380 M | 398 M | 231 M | 231 M | 231 M | 231 M | 263 M | 263 M | 263 M | 263 M | 253 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 980 M | 231 M | 456 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
16.1 M | $ 1.3 | - | $ 7.09 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 5.01 | 6.26 % | $ 831 M |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.26 | 0.31 % | $ 252 M |  USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
15.6 M | $ 1.06 | -6.19 % | $ 293 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.27 | -3.93 % | $ 588 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 13.88 | -1.53 % | $ 914 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 221.31 | 0.4 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.18 | -2.93 % | $ 7.65 B |  Australia |
 |
Catalyst Pharmaceuticals
CPRX
|
851 M | $ 24.01 | 1.65 % | $ 2.84 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
CorMedix
CRMD
|
82.1 M | $ 11.08 | -3.57 % | $ 564 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
2.24 B | $ 57.6 | 1.62 % | $ 4.86 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
BioVie
BIVI
|
21.6 M | $ 1.39 | -4.03 % | $ 2.05 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
22.5 B | $ 94.09 | -0.76 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 26.23 | 3.8 % | $ 1.27 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | $ 10.87 | 0.65 % | $ 1.41 B | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.57 | 0.05 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
31.7 M | $ 16.36 | -2.07 % | $ 420 M | USA |
 |
Exelixis
EXEL
|
2.95 B | $ 41.5 | 1.5 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
|
Foghorn Therapeutics
FHTX
|
284 M | $ 4.48 | 0.82 % | $ 246 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 551.02 | -2.35 % | $ 41.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 91.14 | 1.46 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 8.88 | -1.33 % | $ 1.46 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.08 B | $ 11.43 | -0.87 % | $ 739 M | USA |
 |
Biogen
BIIB
|
28 B | $ 173.99 | -0.06 % | $ 25.3 B | USA |
 |
Abeona Therapeutics
ABEO
|
64 M | $ 5.13 | -4.38 % | $ 110 M | USA |